The $1 Billion Warning Every State Government Should Be Talking About

The public-sector conversation surrounding GLP-1 medications has changed significantly over the past two years. What began largely as a discussion about clinical innovation has become a much broader debate about health plan sustainability, taxpayer exposure, Medicaid budgets, public employee benefits, and the long-term cost of metabolic disease.

North Carolina has become one of the clearest examples of the fiscal pressure involved. The North Carolina State Health Plan, which covers approximately 750,000 state employees, retirees, teachers, and dependents, ended coverage of GLP-1 medications for weight loss after plan officials warned that continued utilization trends could produce extraordinary long-term costs. GLP-1 use among plan members increased more than 700 percent in just a few years, from fewer than 3,000 members in 2021 to more than 23,000 members in 2023. State officials cited annual cost estimates of roughly $170 million and warned that spending could exceed $1 billion over several years.

Why State Governments Face a Different Problem

Private employers are also facing GLP-1 cost pressure, but state governments operate under a different set of constraints. Public employee benefits are funded through appropriations, payroll contributions, employee contributions, and taxpayer-supported budgets. When health plan costs increase materially, the impact may compete with other public priorities, including education, public safety, transportation, infrastructure, Medicaid, and pension obligations.

The Missing Measurement Framework

One of the most significant gaps in public-sector health strategy is longitudinal measurement. State health plans can usually report total spending, prescription utilization, medical trend, pharmacy trend, and enrollment. Those metrics are necessary, but they do not answer the central question: is the population becoming metabolically healthier over time? Without that answer, policymakers are managing expenditures without a clear view of outcomes.

The states that manage this challenge most effectively will likely be those that move beyond a narrow pharmacy debate. The real issue is whether governments can build sustainable metabolic health strategies that improve outcomes, measure progress, and reduce long-term disease burden.